Emergent BioSolutions Inc EBS

Healthcare Biotechnology

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

NYSE:EBS - Post by User

Emergent BioSolutions Inc

<< Previous

Bullboard Posts

Next >>

Post by AviseAnalyticson Jun 27, 2022 8:05am

221 Views

Post# 34783975

HERE’S WHY EMERGENT BIOSOLUTIONS IS WORTH INVESTING!

$EBS

Emergent BioSolutions, Inc. (NYSE:EBS), a life sciences company is developing a portfolio of vaccines and therapeutics for urgent health threats, announced the acceptance of a Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) by the U.S. Food and Drug Administration (FDA).

Here's what you need to know before investing in the Company!

https://www.aviseanalytics.com/heres-why-emergent-biosolutions-is-worth-investing/

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project